Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Afelimomab.

J L Vincent1

  • 1Department of Intensive Care, Erasme Hospital, Free University of Brussels, Belgium.

International Journal of Clinical Practice
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Anti-tumour necrosis factor-alpha (TNF-alpha) therapies, like afelimomab, show promise in treating sepsis by reducing inflammation. Further research is needed to identify specific patient groups who will benefit most from this treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Core competencies in critical care for general medical practitioners in South Africa: A Delphi study.

The Southern African journal of critical care : the official journal of the Critical Care Society·2024
Same author

Proceedings of resources for optimal care of acute care and emergency surgery consensus summit Donegal Ireland.

World journal of emergency surgery : WJES·2017
Same author

Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).

World journal of emergency surgery : WJES·2017
Same author

Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery.

British journal of anaesthesia·2015
Same author

Recent negative clinical trials in septic patients: maybe a good thing?

Minerva anestesiologica·2015
Same author

Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients.

Minerva anestesiologica·2014
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Area of Science:

  • Immunology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Tumour necrosis factor-alpha (TNF-alpha) is a critical mediator in the inflammatory response during sepsis.
  • TNF-alpha plays a significant role in septic shock and multiple organ failure.
  • Anti-TNF-alpha therapies have demonstrated efficacy in inflammatory conditions like rheumatoid arthritis and Crohn's disease.

Purpose of the Study:

  • To evaluate the safety and potential efficacy of afelimomab, an anti-TNF-alpha antibody fragment, in patients with sepsis.
  • To assess the tolerability of afelimomab in a clinical trial setting.
  • To explore the potential benefits of afelimomab in specific patient subgroups with sepsis.

Main Methods:

  • Afelimomab, an F(ab')2 fragment of a murine anti-TNF-alpha antibody, was administered to septic patients.

Related Experiment Videos

  • Clinical trials were conducted to assess the drug's safety profile and therapeutic effects.
  • A large, randomized clinical trial in severe sepsis patients was recently completed.

    • Main Results:

    • Afelimomab was generally well-tolerated in clinical trials involving septic patients.
    • Preliminary results suggest potential benefits for certain patient groups experiencing sepsis.
    • The results of a large, randomized trial in severe sepsis are pending.

    Conclusions:

    • Afelimomab is a well-tolerated therapeutic agent for sepsis.
    • Targeting TNF-alpha with afelimomab may offer benefits in sepsis management.
    • Further investigation is required to identify patient selection criteria for optimal afelimomab therapy in sepsis.